美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

基因編輯

271.11

-6.1748-2.23%

漲家數：2

跌家數：4

平家數：- -

市盈率：- -

高：278.71

開：274.82

低：258.96

收：277.28

資料載入中...

Crispr Therapeutics Ag盤中異動早盤股價大跌5.05%

Editas Medicine, Inc.盤中異動早盤大幅下挫5.36%

Intellia Therapeutics, Inc.盤中異動快速下跌5.01%

Editas Medicine, Inc.盤中異動早盤急速下挫5.08%報1.12美元

Crispr Therapeutics Ag盤中異動股價大跌5.38%

Beam Therapeutics Inc.盤中異動早盤急速下跌9.09%

BUZZ-基因療法製造商因食品藥物管理局官員彼得-馬克斯辭職的報導而下滑

青鳥生物收到非約束性競標，競標價高達 1.105 億美元

BUZZ-受收購要約影響，藍鳥生物股價尾盤大漲 11

藍鳥生物公司公佈截至 12 月 31 日的季度業績 - 收益摘要

BEAM突破0.01美元

BEAM突破0.008美元，24小時漲幅達21.4%

藍鳥生物公司預計每股虧損6.15美元——收益預覽

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4556/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"基因編輯","latestPrice":271.1092,"timestamp":1743796799999,"preClose":277.28403,"halted":0,"volume":73708770,"delay":0,"changeRate":-0.022269,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-6.174835,"latestTime":"04-04 16:00:00 EDT","open":274.81546,"high":278.71335,"low":258.95914,"amount":257226194.034891,"amplitude":0.071242,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.400557,"peRate":-2.791635,"turnoverRate":0.13459,"increases":2,"decrements":4,"flats":0,"marketCap":5292862692,"floatMarketCap":4736099624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":278.71335,"amplitude":0.071242,"preClose":277.28403,"low":258.95914,"pbRate":"1.400557","latestPrice":271.1092,"volume":73708770,"delay":0,"open":274.81546,"prevYearClose":376.62552,"prevWeekClose":330.1375,"prevMonthClose":297.7814,"prevQuarterClose":297.7814,"fiveDayClose":330.1375,"twentyDayClose":413.6838,"sixtyDayClose":407.9273,"secType":"PLATE","market":"US","turnoverRate":0.13459,"peRate":-2.791635,"marketCap":5292862692,"floatMarketCap":4736099624,"timestamp":1743796799999,"nameCN":"基因編輯"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":2,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524279789","title":"Crispr Therapeutics Ag盤中異動 早盤股價大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524279789","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524279789?lang=zh_tw&edition=fundamental","pubTime":"2025-04-04 22:50","pubTimestamp":1743778244,"startTime":"0","endTime":"0","summary":"北京时间2025年04月04日22时50分，Crispr Therapeutics Ag股票出现异动，股价大幅下跌5.05%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体跌幅为1.65%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics AG是一家基因编辑公司，专注于开发基于Crispr/Cas9的疗法。Crispr/Cas9是成簇的规则间隔短回文重复序列/Crispr相关蛋白9的缩写，是精确改变基因组DNA特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040422504494cc1356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040422504494cc1356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","CRSP","BK4556","BK4588","LENZ","LU1861558580.USD","BK4611","LU1861559042.SGD"],"gpt_icon":0},{"id":"2524166784","title":"Editas Medicine, Inc.盤中異動 早盤大幅下挫5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524166784","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524166784?lang=zh_tw&edition=fundamental","pubTime":"2025-04-04 22:47","pubTimestamp":1743778051,"startTime":"0","endTime":"0","summary":"北京时间2025年04月04日22时47分，Editas Medicine, Inc.股票出现波动，股价大幅下挫5.36%。Editas Medicine, Inc.股票所在的生物技术行业中，整体跌幅为1.70%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040422473294cc12ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040422473294cc12ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4556","EDIT"],"gpt_icon":0},{"id":"2524781538","title":"Intellia Therapeutics, Inc.盤中異動 快速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524781538","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524781538?lang=zh_tw&edition=fundamental","pubTime":"2025-04-04 22:43","pubTimestamp":1743777821,"startTime":"0","endTime":"0","summary":"北京时间2025年04月04日22时43分，Intellia Therapeutics, Inc.股票出现异动，股价大幅下挫5.01%。Intellia Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.39%。Intellia Therapeutics, Inc.公司简介：Intellia Therapeutics 是一家基因编辑公司，致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系，以推进其产品线的发展，其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404224341972e84aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404224341972e84aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","BK4588","BK4535","BK4556","LENZ","BK4585","BK4139","LU1861559042.SGD","NTLA"],"gpt_icon":0},{"id":"2524265673","title":"Editas Medicine, Inc.盤中異動 早盤急速下挫5.08%報1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524265673","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524265673?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 21:37","pubTimestamp":1743687470,"startTime":"0","endTime":"0","summary":"北京时间2025年04月03日21时37分，Editas Medicine, Inc.股票出现异动，股价急速跳水5.08%。Editas Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Protagenic Therapeutics, Inc.、Osr Holdings, Inc.、Context Therapeutics Inc.涨幅较大，Protagenic Therapeutics, Inc.、Genprex, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为1217.27%、326.96%、105.35%，振幅较大的相关个股有Protagenic Therapeutics, Inc.、Context Therapeutics Inc.、Osr Holdings, Inc.，振幅分别为52.42%、23.89%、19.73%。Editas Medicine, Inc.公司简介：Editas Medicine Inc 是一家临床阶段基因组编辑公司，致力于开发具有潜在变革性的基因组药物来治疗各种严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321375094cb2cf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321375094cb2cf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4556","EDIT"],"gpt_icon":0},{"id":"2524248250","title":"Crispr Therapeutics Ag盤中異動 股價大跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524248250","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524248250?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 21:30","pubTimestamp":1743687059,"startTime":"0","endTime":"0","summary":"北京时间2025年04月03日21时30分，Crispr Therapeutics Ag股票出现波动，股价大幅下挫5.38%。Crispr Therapeutics Ag股票所在的生物技术行业中，整体涨幅为0.00%。Crispr Therapeutics Ag公司简介：CRISPR Therapeutics AG是一家基因编辑公司，专注于开发基于Crispr/Cas9的疗法。Crispr/Cas9是成簇的规则间隔短回文重复序列/Crispr相关蛋白9的缩写，是精确改变基因组DNA特定序列的革命性技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403213100a6ae9652&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403213100a6ae9652&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4139","BK4585","LU1861558580.USD","LU1861559042.SGD","BK4611","BK4556","CRSP"],"gpt_icon":0},{"id":"2524684242","title":"Beam Therapeutics Inc.盤中異動 早盤急速下跌9.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524684242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524684242?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 21:30","pubTimestamp":1743687044,"startTime":"0","endTime":"0","summary":"北京时间2025年04月03日21时30分，Beam Therapeutics Inc.股票出现异动，股价急速下跌9.09%。Beam Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Beam Therapeutics Inc.公司简介：Beam Therapeutics Inc 是一家生物技术公司，致力于基于其专有的碱基编辑技术开发一类新的精准基因药物，为患有严重疾病的患者提供终身治愈方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403213044aa2c57f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403213044aa2c57f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4611","BK4585","BK4588","BEAM","BK4505","BK4139","BK4556","LENZ"],"gpt_icon":0},{"id":"2524992786","title":"BUZZ-基因療法製造商因食品藥物管理局官員彼得-馬克斯辭職的報導而下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2524992786","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524992786?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 00:28","pubTimestamp":1743438489,"startTime":"0","endTime":"0","summary":"3月31日 - ** 在《华尔街日报》等媒体报导美国食品及药物管理局高层官员彼得-马克斯被赶出该机构后，基因疗法生产商和开发商的股价下滑   ** 马克斯曾任美国食品及药物管理局生物制品评估与研究中心主任，并在任职期间推出了多项加速基因和细胞疗法发展的计划。** 据《华尔街日报》报导，卫生与公众服务部的一位官员让马克斯选择辞职或被解雇，该报导还称马克斯的辞职将于 4 月 5 日生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3T3QE131:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","SRPT","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4556","SLDB","BK4611","BK4535","BK4588","BK4139","TSHA","BK4585","IE00BJJMRZ35.SGD","BK4505","IE00BJT1NW94.SGD","IE0002141913.USD","BEAM"],"gpt_icon":0},{"id":"2523639510","title":"青鳥生物收到非約束性競標，競標價高達 1.105 億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523639510","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523639510?lang=zh_tw&edition=fundamental","pubTime":"2025-03-29 05:39","pubTimestamp":1743197945,"startTime":"0","endTime":"0","summary":"路透社3月28日 - 基因治疗生产商蓝鸟生物BLUE.O周五表示，它已收到同行Ayrmid公司提出的不具约束力的报价，最高可达1.105亿美元，其股价在延时交易中上涨了9.8%，报收于4.40美元。根据路透社利用 LSEG 编制的数据计算，细胞疗法开发商 Gamida Cell 的母公司 Ayrmid 提出以每股 4.50 美元的预付款收购蓝鸟，总价约为 4380 万美元。蓝鸟公司表示，其董事会正在与法律和财务顾问协商审查Ayrmid公司的建议，董事会没有改变支持凯雷和SK Capital Partners交易的建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3T3QB1KY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","CG","IE00B3QW5Z07.USD","BK4578","IE00B64PRP62.GBP","BK4139","BK4135","BLUE","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2523366096","title":"BUZZ-受收購要約影響，藍鳥生物股價尾盤大漲 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2523366096","media":"路透中文","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523366096?lang=zh_tw&edition=fundamental","pubTime":"2025-03-29 05:20","pubTimestamp":1743196815,"startTime":"0","endTime":"0","summary":"** BLUE 的股价在周五常规交易结束时上涨了 7.7%，报收于 4.08 美元。根据双方达成的协议，BLUE 将以每小时 3.00 美元的现金和每小时 6.84 美元的一次性或有价值权被私有化。** BLUE表示正在审查Ayrmid的建议，但仍受凯雷/SK交易条款的限制，其董事会没有改变支持合并的建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3T3QB1K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BLUE","BK4578"],"gpt_icon":0},{"id":"2522757518","title":"藍鳥生物公司公佈截至 12 月 31 日的季度業績 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2522757518","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522757518?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 14:10","pubTimestamp":1743142202,"startTime":"0","endTime":"0","summary":"蓝鸟生物公司公布截至 12 月 31 日的季度业绩 - 收益摘要蓝鸟生物公司BLUE.OQ公布的截至12月31日的季度调整后每股亏损为2.95美元，高于去年同期的每股收益15.60美元。七位分析师对该季度的平均预期是每股亏损 5.98 美元。华尔街预期为每股亏损 8.25 美元至 3.65 美元。蓝鸟生物公司公布的本季度每股收益为亏损 2.95 美元。该公司一季度亏损2864万美元。本季度蓝鸟生物公司股价下跌了 54.6%。华尔街对蓝鸟生物公司 12 个月目标价的中位数为 8.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3T3QB0GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BK4556","BLUE","BK4139"],"gpt_icon":0},{"id":"2522998362","title":"BEAM突破0.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522998362","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522998362?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 09:32","pubTimestamp":1743039136,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.coingecko.com/zh/%E6%95%B0%E5%AD%97%E8%B4%A7%E5%B8%81/beam-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BK4556","BK4505","BK4585","BK4535","BEAM","BK4588","BK4611","BK4139"],"gpt_icon":0},{"id":"2521637248","title":"BEAM突破0.008美元，24小時漲幅達21.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521637248","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521637248?lang=zh_tw&edition=fundamental","pubTime":"2025-03-22 23:58","pubTimestamp":1742659116,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.coingecko.com/zh/%E6%95%B0%E5%AD%97%E8%B4%A7%E5%B8%81/beam-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BK4585","BK4535","BK4611","BEAM","BK4505","BK4139","BK4588","BK4556"],"gpt_icon":0},{"id":"2521289016","title":"藍鳥生物公司預計每股虧損6.15美元——收益預覽","url":"https://stock-news.laohu8.com/highlight/detail?id=2521289016","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521289016?lang=zh_tw&edition=fundamental","pubTime":"2025-03-21 21:06","pubTimestamp":1742562370,"startTime":"0","endTime":"0","summary":"伦敦证券交易所集团分析师对蓝鸟生物公司的平均预期是每股亏损6.15美元。华尔街对bluebird bio Inc的12个月目标价中值为8.00美元，高于其最后收盘价3.96美元。3月21日 - 上一季度业绩。除非另有说明，所有数据均以美元为单位。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL4T3Q410H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BK4578","BLUE"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13}]}}